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Abstract 10 
Drug administration through transdermal delivery is restricted by the top layer of skin, the 
stratum corneum. One possible solution to overcome the barrier function of the stratum 
corneum is to employ microneedle arrays. However, detailed theoretical models relating drug-
coated microneedles and their geometry to the drug concentration in the blood are limited. 
This paper aims to address this issue by examining the blood concentration profiles for a 15 
model drug, insulin, that has been administered via coated microneedles. A mathematical 
model is introduced and applied to predict theoretical blood concentrations. Furthermore, the 
insulin concentration in blood is calculated for a range of different microneedle shapes and 
dimensions to identify the most effective geometry. The results indicate that the optimum 
microneedle geometry in terms of maximimizing insulin concentration was a rocket shaped 20 
needle that has a constant tip angle of 90º. Also, it has been found that the number of 
microneedles in an array is the most significant factor in determining maximum insulin 
concentration in the blood (Cb,max). 
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1. Introduction 35 
In order to understand the mechanisms of microneedle-mediated transdermal drug delivery, it 
is first necessary to analyze the skin structure. The epidermis consists of two main layers; the 
stratum corneum (SC) and the viable epidermis (VE). The typical thickness of SC is 10 -15 
µm although it can be as much as 40 µm in some parts of the human body.[1] The SC consists 
of flat layer of dead cells filled with keratin fibres and surrounded by lipids.[2] Below this 40 
layer lies the viable epidermis which consists of living keratinocytes and a very small amount 
of nerve endings.[3] This layer is typically 50 -100 µm thick.[4] The epidermis is separated 
from the dermis by a protein rich basement membrane. The dermis forms the majority of the 
skin volume and contains living cells, a rich microcapillary network and nerve endings. The 
distance from the skin surface to the microcirculation has been reported as 200 µm.[5] This 45 
layer also provides structural support and elasticity to the epidermis layer.[6] The absolute 
thicknesses of each layer can vary with age, sex and ethnicity, as well as between individuals. 
Skin thickness also changes according to the anatomical site being considered.[7] 
 
It has been suggested that in a transdermal diffusion model, the skin acts as a two layer 50 
membrane which consists of the SC and the viable skin. When a drug permeates through the 
viable skin, it is rapidly absorbed by the microcirculation.[5] The stratum corneum is the main 
barrier to diffusion through the skin. This is due to the diffusion coefficient for drug 
molecules being typically 500-10,000 times smaller in the stratum corneum than within the 
viable skin.[5] 55 
 
Microneedles have been proven to be a useful means to continuously deliver drug molecules 
to the blood.[8,9] This paper has focused on modelling insulin delivery from a microneedle 
system. Insulin delivery is needed for various medical reasons such as lowering the blood 
glucose levels in the treatment of diabetes,[10] reducing the infarct size and hence improving 60 
the diagnosis of the patient once the stroke occurred,[11] etc. In fact, insulin has been adopted 
as a model drug in many studies for transdermal drug delivery using microneedles.[10,12-15] We 
choose insulin as a model drug for the purposes of this paper. 
 
Arranged into an array, microneedles are micron-scale projections that penetrate through the 65 
stratum corneum, creating pathways through which drugs can diffuse into the deeper levels of 
the skin. Microneedles are considered to be a hybrid between hypodermic needles and 
transdermal patches, combining the advantages of both while overcoming their 
shortcomings.[16] Hypodermic needles are able to effectively deliver a drug but are associated 
with pain and the need for medical expertise that generally precludes self-administration. 70 
Microneedles can be broadly categorized into two types, hollow or solid (coated). Hollow 
microneedles have generally received less attention to date as their structure is inherently 
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weak and they have practical problems such as the bore hole being clogged by tissue.[17] On 
the other hand, according to Gill and Prausnitz,[18] coated microneedles could potentially 
provide an alternative means to systemically deliver drugs in a bolus form. It has been noted 75 
that the drug coating should be localised on the microneedle surface rather than the array 
base. Even though coating the base of the array could increase the dosage, it has been found 
that the drug is poorly delivered from the array base and instead most drugs are delivered 
from the tips of the microneedles.[18] For example, when the model antigen ‘ovalbumin’ was 
coated onto the tips of a microneedle array its delivery efficiency was increased by 48-58%[19]  80 
compared to 4-14% when the whole array was coated.[20] The coating should adhere well to 
the microneedles in order to avoid deposition of the drug on the skin’s surface during 
insertion. This will increase delivery efficiency and is also beneficial from safety 
perspective.[19] This paper describes a model for coated microneedles, the so-called “coat and 
poke” approach[15] as shown in Figure 1. 85 
 
Martanto et al.[14] studied whether skin permeability to insulin can be enhanced by using a 
microneedle array while insulin solution is applied topically in a so-called “poke with patch” 
method.[15] Solid microneedles coated with insulin have been applied to diabetic hairless rats 
where the decrease in blood glucose levels was significantly greater than in the control case 90 
when microneedles were not used.[14] The initial concentration of the drug decreases over time 
to an ineffectual stage once the drug penetrates into human skin. Therefore, to reach an 
effective blood concentration, the therapeutic efficacy of drug should be improved by 
increasing drug administration.[21] Kolli and Banga[22] show that the plasma drug 
concentration reaches its maximum when using microneedles as compared to passive 95 
delivery. 
 
Moreover, our previous work showed the influence of different factors (e.g., microneedle 
length, surface area of the patch, etc) on the steady-state of blood drug concentration.[23] This 
study has been administered by presenting a parametric analysis for transdermal delivery of 100 
drugs with both high and low molecular weights. A dimensional analysis has been carried our 
using Buckingham's π theorem to determine the functional dependence of blood drug 
concentration on various parameters. In another study, we have presented a mathematical 
framework to examine the influence of various coated microneedle dimensions (e.g., 
microneedle thickness, microneedle diameter, etc) on drug permeability.[24] Both the effective 105 
skin thickness and permeability have been determined for six microneedle models. The 
effects on the ratio of permeability (RP) for skin with microneedles to normal skin have also 
been determined.[24] Motivated by this work,[24] this paper seeks to further study the effects of 
several geometrical parameters (e.g., microneedle thickness, coating depth, etc) on the insulin 
blood concentration profiles. It is rare to find a study that has systematically addressed how 110 
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the microneedle array design parameters influence drug blood concentration profiles from a 
computational point of view. This work is envisaged to determine the maximum insulin 
concentration in the blood for various microneedle models, and hence identify the optimum 
model, if any, for the transdermal drug delivery of insulin. 
 115 
2.  Description of the Modelling Framework 
To model the diffusion process from the coated microneedles into the skin and determine the 
effects of geometry, six microneedles shapes have been selected as shown in Figure 2. These 
models have been chosen based on what has been reported in the literature, though they are 
not all drawn to scale. These models are the same as discussed in our previous work.[24] A 120 
schematic diagram of the developed mathematical framework for insulin transport across the 
skin via a microneedle array is illustrated in Fig. 1. Solid microneedle arrays are coated by an 
aqueous solution of insulin molecules which bypass the stratum corneum.[24] Insulin 
molecules diffuse across viable epidermis until they reach the epidermal-dermal junction  
where they are absorbed by the microcirculation. In the figure Lu is the length of the uncoated 125 
microneedles, L is the penetration depth of microneedles, H is the thickness of the skin after 
microneedles have been inserted (i.e., the distance between the tip of the microneedle and the 
blood microcirculation), h is the epidermis thickness and S is the microneedle centre-to-centre 
spacing. Insulin pharmacokinetics are described by a one compartment model (i.e. blood 
compartment) with first order elimination kinetics.[5] 130 
 
In this section, the model assumptions in the mathematical framework have been presented. 
Then, the governing equations of both the diffusive flux and drug concentration in blood 
along with their initial and boundary conditions have been given and explained in detail.   
 135 
2.1 Model Assumptions 
When considering the delivery of insulin from the microneedles through the skin, the 
following assumptions are made in this work:[24] 
(i) The concentration of insulin in the blood remains low compared the insulin 
concentration on the microneedle, and so the blood is considered to act as a sink.[25] 140 
(ii) Skin binding of insulin is assumed to be negligible in the viable skin. 
(iii) Insulin metabolism is assumed to be negligible in the viable skin. 
(iv) The insulin molecules that diffuse through the viable skin to the interface between 
viable skin and blood microcirculation are taken up by the  microcirculation. 
(v) Diffusion through the skin is the rate limiting step in the uptake of insulin. 145 
The detailed justifications of these assumptions have been avoided in this paper since they are 
explained by Davidson et al.[24] However, these assumptions may be briefly explained as  
below. 
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The stratum corneum is mainly impermeable to insulin due to the intercellular lipid layers.[26] 150 
The partition coefficient  on the boundary between the viable epidermis and dermis has been 
assumed to be equal one since  both layers (i.e., viable epidermis and dermis) consist mainly 
of water.[27] Drug partition in the skin was not considered during an intracutaneous injection 
as the diffusion coefficient was considered more important than the partition coefficient.[28] 
McAllister et al.[16] develop a theoretical model to determine the skin permeability of various 155 
macromolecules, including insulin, when using microneedle. The permeability was a function 
of the microneedle dimensions, skin thickness and drug diffusivity and the partition 
coefficient was not considered. The results agreed well with the experimental data. 
 
Microneedles have been shown to be a promising technique for achieving effective drug 160 
delivery to the blood stream.[29] The drug is absorbed almost completely by the blood vessels 
once the drug diffuses across the viable epidermis.[5,30] In another study, it has been shown 
that almost 97% of the drug is taken up by the blood stream.[31] Furthermore, the blood 
glucose levels in diabetic hairless rats has been reduced by 80% when using an array of solid 
microneedles and an insulin solution placed in contact with the skin.[14] The drop in blood 165 
glucose levels due to insulin delivery from microneedles was found to be comparable to that 
from a hypodermic injection of 0.05-0.5 U insulin (μU/mL = 0.0417 µg/L). These results 
indicate that microneedles can successfully deliver drugs such as insulin in vivo and  the 
majority of the insulin is absorbed by the blood microcirculation. Ito et al.[13] concluded that 
insulin administered through microneedles was well absorbed by the blood stream. 170 
 
2.2 Governing Equations for Diffusive Flux from Coated Microneedles 
The movement of insulin across the viable skin is represented by Fick's second law of 
diffusion as 
2
2
x
CD
t
C
∂
∂=∂
∂
           (1) 175 
Where C [unit.m-3] is the concentration of insulin, t [s] is time, D [m2.s-1] is the diffusion 
coefficient of insulin and x [µm] is the path length of insulin molecules in a given skin layer. 
 
In order to solve the above equation, the following Dirichlet type initial and boundary 
conditions have been imposed. 180 
The initial concentration of insulin in the microneedle coating is 
0tforLxLat0CC u0m =<<==       (2) 
The boundary conditions for the insulin concentration of coated microneedles are: 
At the surface of the coated microneedles, the concentration of insulin is 
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0tforLxLatCC um ><<=       (3) 185 
At the epidermal-dermal junction, the concentration of insulin is 
0tforhxat0C >==         (4) 
In equations (2) – (3), Cm0 [unit.m-3] is the initial concentration of insulin in the microneedle 
coating, Cm [unit.m-3] is the concentration of insulin in the microneedle coating, Lu [µm] is the 
uncoated microneedle length, L [µm] is the penetration depth of microneedle and h [µm] is 190 
the thickness of epidermis which is defined to be equal to 200 µm in this work.[5] 
 
Under the above assumptions, the steady state flux of insulin, Jss [unit.m-2.s-1], is given as 
follows:[24,32] 
mss PCJ =           (5) 195 
Where P [m.s-1] is the insulin permeability in the viable skin and Cm [unit.m-3] is the 
concentration of insulin in the microneedle coating as mentioned before. In our case we have 
defined the effective thickness Heff [m] of the skin after microneedles have been inserted as a 
function of microneedle geometry:[24] 
ss
mvs
eff J
CD
H =          (6) 200 
Where Dvs [m2.s-1] is the diffusion coefficient of insulin in the viable skin, Heff is the effective 
skin thickness (i.e., effective path length of molecules in tissue) that insulin molecules can 
pass in the tissue from coated microneedle which depends on the needle geometry[24] and ssJ  
[unit.m-2.s-1] is the average steady state flux depending on the needle geometry. The diffusion 
coefficient of insulin in the viable skin is assumed to be constant on the basis that the 205 
diffusion coefficients in both the viable epidermis and dermis are of the same magnitude.[5] 
 
Diffusion of insulin in the skin from the coated microneedles has been modelled in 3D using 
FEMLAB®, a general partial differential equations solver from Comsol.[33] FEMLAB® is 
based on finite element method to solve partial differential equations. This has been done by 210 
discretizing  or ‘meshing’, the domain of interestinto a set of small tetrahedral elements. 
 
The flux term determined from the simulations has been integrated over the microcirculation 
boundary and then divided by the boundary area (i.e. 100µm x 100µm = 28 m101 −× ) to give 
an average steady state flux. This value has been used to calculate the effective skin thickness 215 
(Heff) as discussed in detail by Davidson et al.[24] This result has been used in the governing 
equations of blood insulin concentration as has been discussed in the following section. 
 
2.3 Governing Equations for Insulin Concentration in Blood 
 
 
7
For the purpose of this work, the insulin concentration in blood after imposing the 220 
transdermal drug delivery is given by a one-compartmental pharmacokinetic model:[23,31] 
bbea
b
b VCKSdt
dQ
dt
dC
V −⎟⎠
⎞⎜⎝
⎛=        (7) 
Where, Ke is the elimination rate constant from the blood compartment, dQ/dt is the 
penetration rate of insulin through the skin, Sa is the surface area of the delivery system (i.e., 
patch of microneedles), Vb is the volume of distribution in the blood and Cb is the insulin 225 
concentration in the blood. 
 
The distance to the blood microcirculation from the skin surface has been reported as 200 
µm,[5] which is used here as well. The viable skin is modelled as a single domain with a single 
isotropic diffusion coefficient. The width and length of the square element of skin represents 230 
the centre-to-centre spacing of the microneedles, assuming they are in a square pattern as 
shown in Figure 1. The spacing has been assumed to be 100 µm, leading to an area for a 
square element of skin equal to 28 m101 −× . The governing equations (1)-(4) & (7) have 
been solved by applying the software, SKIN-CAD®.[34] For brevity, the working principles of 
this software have been avoided as explained previously.[23,31] 235 
 
This one-compartment model, the simplest pharmacokinetic model, mimics the drug transport 
behaviour in this case. One assumption that is being made for the above model is that the drug 
distribution and concentration equilibrium occur rapidly.[35] It is therefore adequate to 
describe the pharmacokinetics of drugs that minimally distribute into the body’s tissue.[36] As 240 
mentioned earlier, the one-compartment model has been used in this paper where we apply 
the values for the volume of distribution (Vb) and the elimination rate constant (Ke) obtained 
from literature for insulin. The one-compartment model with steady state values provides a 
good approximation, especially for those drugs that distribute and reach steady state quickly. 
Moreover, the one-compartment model is more appropriate for a drug when using transdermal 245 
drug delivery (e.g., hypodermic injection, microneedle arrays) than for an oral delivery (e.g., 
pill), which takes time to dissolve, absorb, and distribute into the system.[37] Therefore it is 
sufficient for the purpose of this work, i.e., to determine the effects of microneedle geometry 
with insulin as a model drug. 
 250 
3. Results and Discussions 
In our simulations, the concentration of insulin in blood has been calculated using equation 
(7). The diffusion coefficients in the viable skin (Dvs) for a number of drugs are not well 
known. However, insulin, with a molecular weight (MW) of 5800, has been estimated to have 
a Dvs of 10101 −× m2s-1.[16,38] Average values of the volume of distribution in the blood (Vb) 255 
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and the elimination rate constant from the blood compartment (Ke) for particular drugs have 
been documented in literature, as they tend to vary among individuals. However, according to 
Van Rossum[36] these two parameters have values of 21L and 0.46 h-1, respectively. We have 
defined that the concentration of drug in the microneedle coating Cm is 1 unit/m3. Unless 
otherwise stated, the insertion time of microneedles has been assumed to be four hours. 260 
 
3.1 Validation of the developed approach 
We start our discussion by validating the simulations carried out in this mathematical 
framework. This has been done by comparing the numerical results with the experimental 
work by Martanto et al.[14] as shown in Figure 3. It should be noted that only two points were 265 
taken in the experimental results. The results show that the simulation results compare 
adequately with the experimental results. It must be pointed out that the results are for cases 
when the microneedles have been inserted into diabetic hairless rat. Therefore, an animal skin 
has been used because of the difficulties of using human skin for various reasons such as 
ethical consideration.[39] However, a review has been presented to compare various skins 270 
including human and animal skins.[40] In this study, the authors have concluded that mammal 
skin is a reasonable model to study transdermal delivery in humans.[40] 
 
3.2 Effects of microneedle shapes on insulin distribution in skin 
In order to determine the effectiveness of transdermal drug delivery using microneedles, the 275 
distribution of blood insulin concentrations for each microneedle model has been obtained. In 
a previous work involving different needle geometries, Lv et al.[38] have used a theoretical 
model to obtain insulin profiles across the skin. They studied both the transient and spatial 
distribution in the skin tissue as well as in the drug solution. However, they have not 
considered the implications of variations in the microneedle geometry. In our study, the 280 
distribution of insulin concentration across skin for various microneedles models has been 
simulated as shown in Figures 4 and 5. As expected, the insulin concentration decreases 
gradually towards the blood interface due to sink condition there. It seems the most effective 
model is microneedle model D as the distribution of insulin concentration (i.e., 0.5 ≤Cins≤ 1 
unit/m3) covers most of the skin thickness (i.e., 200 µm). On the other hand, microneedle 285 
model B results in the least distribution of insulin concentration. The uniform distribution is 
an important factor that can be observed in microneedle models C and E. In microneedle 
model C, the drug is distributed mostly on one side. This is due to the cylindrical shape of 
microneedle with a bevelled tip. However, in microneedle model E, the drug is mainly 
distributed around the top of the microneedle. This is also due to its arrow-head shape. Back 290 
diffusion of insulin has also been observed in all cases. 
 
3.3 Effects of penetration depth (L) 
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To address the implications of the penetration depth (L) on insulin concentration in the blood, 
the depth of microneedle penetration for microneedle model A (i.e., cylindrical needle at a 295
constant tip angle of 90º) has been varied. In addition the penetration depth of the various 
microneedle model shapes has been varied to examine the influence of L on the maximum 
insulin concentration in blood (Cb,max). The performance of the drug delivery process for 
microneedle arrays could be improved by relating microneedle geometries to the penetration 
depth.[8] The penetration depth of coated microneedles of the same length with various doses 300 
was observed.[19] However, the depth of penetration was reduced by increasing the 
microneedles length while maintaining the same dose by Widera et al.[19] Cormier et al.[41] 
also found a significant reduction in penetration depth for coated microneedles as compared 
to uncoated microneedles. 
 305 
The maximum insulin concentration in blood (Cb,max) reaches its highest value for a 
penetration depth of 180 µm with a value of 0.65 ng/ml as shown in Figure 6. Penetration 
depth of microneedles in this model represents the depth to which the microneedle penetrates 
the skin, and as such, does not directly represent the physical length of the microneedle. Apart 
from the variable penetration depth, the dimensions have been used as shown in Table 1.  For 310 
all microneedle penetration depth cases, the insulin concentration in blood decreases after 4 
hours as this has been defined as the length of time the microneedles remain inserted. As the 
effective skin thickness (Heff) decreases with deeper penetration by the microneedles,[24] the 
insulin concentration in blood is increased. This implies that by increasing microneedle 
penetration depth, the process of transdermal drug delivery using microneedles has been 315 
enhanced significantly. 
 
To further study the effect of penetration depth, the penetration depth (L) of various 
microneedles models has been changed to observe the effect on the maximum insulin 
concentration in blood as shown in Figure 7. Microneedle model C has not been included due 320 
to the similarity in the geometry of this model, and hence the obtained results, with 
microneedle model A. Microneedle model D is the best model as it has the highest maximum 
insulin concentration in blood (Cb,max) with a value of 0.73 ng/ml corresponding to a 
penetration depth of 180 µm. The results show that there is a proportional relationship 
between the penetration depth (L) and maximum insulin concentration in blood. As such the 325 
penetration depth is a significant factor in determining the maximum insulin concentration in 
blood. 
 
3.4 Effects of centre-to-centre spacing of adjacent microneedles (S) 
In this section, the centre-to-centre spacing (S) of microneedle model B (i.e. cone with a 330 
constant tip angle of 20.2º) has been varied between 75-200 µm to analyze the influence of 
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this parameter on insulin concentration in blood. Microneedle spacing (pitch) is an important 
parameter and hence appropriate microneedle spacing should be determined.[42] So far the 
implications of centre-to-centre spacing have been evaluated in different contexts and rarely 
on drug concentration in blood. For example, the shear stress acting on microneedle tip with 335 
microneedle spacing (i.e., varying from 150 µm to 600 µm) has been examined by Choi et 
al.[42] These authors have shown that the optimum microneedle spacing is 450 µm as it 
corresponded to the lowest stress of approximately 34.5 MPa. In this work the centre-to-
centre spacing of various insulin-coated microneedle shapes has been varied to study the 
impact on the maximum insulin concentration in the blood (Cb,max). Closely spaced 340 
microneedles are associated with difficulty in insertion due to skin elasticity as reported in a 
previous study.[43] 
  
From Figure 8, the maximum insulin concentration in blood of insulin was 0.31 ng/ml. Apart 
from the centre-to-centre spacing, the other dimensions have been kept constant as shown in 345 
Table 1.  As mentioned in the previous results, longer centre-to-centre spacing of 
microneedles result in higher values of Heff.[24] The higher effective skin thickness is offset by 
the increase in the surface area of the microcirculation interface for a given number of 
microneedles, which tends to increase the flux of drug molecules into the blood stream. 
Despite this, increasing microneedle spacing results in generally lower ranges of insulin 350 
concentrations. 
 
The centre-to-centre spacing (S) of the microneedle models was varied to study the influence 
on blood insulin concentrations, as shown in Figure 9. As mentioned previously, microneedle 
model A and microneedle model C have been found to be indistinguishable so microneedle 355 
model C has not been plotted. Microneedle model D is the optimum model as it has the 
highest maximum insulin concentration in blood (Cb,max) with a value of 0.42 ng/ml for a 
spacing of 75 µm. For the range of centre-to-centre spacing studied, the maximum insulin 
concentration in the blood varies significantly in all microneedle models. The results indicate 
there is an inverse relationship between the centre-to-centre spacing (S) and the maximum 360 
insulin concentration in blood. 
 
3.5 Effects of microneedle diameter (d) 
To assess how the microneedle diameter (d) affects the blood insulin concentration, the 
diameter of microneedle model C (i.e., bevelled needle at a constant tip angle of 45º) has been 365 
varied. In addition, the diameter of each microneedle model was varied to evaluate the 
influence on the maximum insulin concentration in blood (Cb,max). Khumpuang et al.[44] have 
claimed that the microneedle diameter should have a diameter greater than the diameter of 
white blood cell (≈ 20 µm) in order to avoid any problem that may arise from blood clogging. 
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In general, larger diameters are advantageous in allowing greater mechanical stability[45] as 370 
the force required to buckle the microneedle during insertion to the skin increases.[46] Teo et 
al.[8] have shown that microneedle-mediated drug delivery could be enhanced by increasing 
microneedle diameters. These results agreed well with the simulations presented by Haider et 
al..[47] In another study, it has been shown that microneedle diameter is related to microneedle 
density, i.e., the number of microneedle per unit area.[3] 375 
 
In previous results presented by Davidson et al.[24] it has been shown that varying microneedle 
diameter does not have a significant influence on the effective skin permeability (Peff). This 
agrees well with our results as the maximum insulin concentration in blood (Cb,max) for 
various diameters did not change significantly and there is a plateau in insulin concentration 380 
of approximately 0.34 ng/ml, as shown in Figure 10. This indicates that by increasing 
microneedle diameter, the process of transdermal drug delivery using microneedles has not 
been enhanced significantly. Other model dimensions have been kept constant as shown in 
Table 1. 
 385 
The microneedle diameter (d) of both microneedles model A and C was varied to observe the 
influence on insulin concentration as shown in Figure 11. Microneedle model A is the 
resulted in the highest maximum insulin concentration in blood (Cb,max) with a value of 0.35 
ng/ml corresponding to a diameter of 60 µm. However, the maximum insulin concentrations 
in blood of both microneedles models were not significantly different, indicating that the 390 
maximum insulin concentration in the blood does not strongly depend on the microneedle 
diameter. Our results suggest that there has been a proportional relationship between 
microneedle diameter (d) and maximum insulin concentration in blood. 
 
3.6 Effects of microneedle insulin coating depth (CD) 395 
The effect of the depth of insulin coating (CD) on the insulin concentration in the blood 
requires further study that is beyond the scope of this paper. However, if we assume that CD 
remains constant during the time that the microneedles are inserted in skin (4 hours in our 
case), we can perhaps gain an insight on how this affects the blood insulin concentration. 
Using the above assumption, the depth of insulin coating (CD) on microneedle model D (i.e., 400 
rocket needle at a constant tip angle of 90º) was varied between 40 to 100 µm to investigate 
the influence of this parameter on insulin concentration in the blood. In addition, the coating 
depth of various microneedle models has been varied to determine the influence of the insulin 
coating depth on the maximum attainable insulin concentration in blood (Cb,max). In previous 
work the drug coating depth (generally 25%-100% of microneedle length coverage) was 405 
examined to study whether uniform drug coating could be achieved.[18] The dose of coated 
ovalbumin was found to significantly influence the degree of immune response, indicating 
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that the size of dose is a significant factor in transdermal drug delivery through microneedle 
arrays.[19] An earlier study presented by Cormier et al.[41] found that drug delivery efficiency 
increased with decreasing coating dose of desmopressin as a model drug. In another study, the 410 
amount of ovalbumin coated on microneedles was increased by increasing the coating 
concentration of ovalbumin which in turn also increased the amount of ovalbumin delivered 
by the microneedles.[20] 
 
Similar to what has been obtained for increasing microneedle diameter, increasing the coating 415 
depth of insulin on the microneedle does not have a very significant effect on the permeability 
ratio Peff,.[24] As a result, the maximum insulin concentration in blood (Cb,max) for the range of 
microneedle diameters being evaluated is almost constant with a value of approximately 0.38 
ng/ml. The results for the effect of microneedle coating depth on the maximum insulin 
concentration in blood are shown in Figure 12. All other dimensions have been kept constant 420 
as shown in Table 1. 
 
The coating depth (CD) was varied on all microneedles models to determine the effect on the 
insulin concentration in the blood as shown in Figure 13. Again, the results from microneedle 
models A and C are indistinguishable and hence microneedle C has been omitted from the 425 
results. Microneedle model D resulted in the highest maximum insulin concentration in blood 
Cb,max with a value of 0.38 ng/ml corresponding to a coating depth of 100 µm. However, over 
the range of coating depth examined the maximum insulin concentration did not change 
significantly. This indicates that the maximum blood insulin concentration does not depend 
significantly on the coating depth. 430 
 
3.7 Effects of microneedle thickness (T) 
The thickness (T) of microneedle model E (i.e., arrow needle at a constant tip angle of 73.8º) 
was varied for insulin between 25 to 75 µm. In addition, the thickness of various microneedle 
models coated with insulin has been varied to examine the influence of the microneedle 435 
thickness on the maximum insulin concentration in blood (Cb,max).  Microneedle thickness has 
been considered a key factor due to its influence on the force required to fracture the 
microneedle.[43] In one study, it was observed that with large microneedle thickness, the 
margin of safety (i.e. ratio between microneedle fracture and skin insertion force) reached its 
highest value. Rajaraman and Henderson[48] have considered the thickness as an important 440 
dimension since it determines the aspect ratio of their fabrication process. 
 
The results shown in Figure 14 indicate that by increasing the thickness of the microneedles, 
the maximum insulin concentration in blood (Cb,max) can be increased. However, over the 
range of thicknesses used, the range of Cb,max is generally smaller when compared to the range 445 
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that has been obtained by varying both penetration depth of microneedle and centre-to-centre 
spacing of microneedles. This is because increasing microneedle thickness results in less 
significant increases in Peff, as shown previously[24]. All other dimensions have been kept the 
same as shown in Table 1. 
 450 
The microneedle thickness (T) of microneedles models D-F was varied to determine the 
influence on the blood insulin concentration as shown in Figure 15. It must be noted that the 
microneedle thickness is only important for in-plane manufactured microneedles (i.e., 
microneedles models D-F). Microneedle model D results in the highest maximum insulin 
concentration in blood (Cb,max) with a value of 0.41 ng/ml corresponding to a thickness of 75 455 
µm. Over the range of microneedles thicknesses chosen, the maximum insulin concentration 
was only slightly changed, indicating that it is a relatively weak function of the microneedle 
thickness. The results indicate a proportional relationship between microneedle thickness (T) 
and the maximum insulin concentration in blood. 
 460 
3.8 Effects of the number of microneedles in the array (N) 
To systematically address the implications of the number of microneedles in the array (N) on 
insulin concentration in the blood, the number of microneedles in the arrays for microneedle 
model F (i.e., wedge needle at a constant tip angle of 20.2º) has been varied. In addition, the 
number of microneedles in the arrays of each microneedle model was also been varied to 465 
examine the effect on the maximum insulin concentration in blood (Cb,max). Since 
microneedles were first introduced, varying numbers of microneedles per array have been 
fabricated. Examples of microneedle number in literature vary between 9[49] and 657.[19] 
According to Stoeber and Liepmann,[3] the efficiency of transdermal drug delivery improves 
with increasing numbers of microneedles in the array. Park et al.[50] have claimed that by 470 
increasing the number of microneedles in the arrays, skin permeability increases. Gill and 
Prausnitz[18] have found that by increasing the number of microneedles in the arrays, it was 
possible to increase the amount riboflavin coated to the array. On the other hand, the delivery 
of a given antigen dose did not depend on the number of microneedles in the array.[19] Ito et 
al.[13] have shown that plasma glucose level does not change significantly by reducing the 475 
number of microneedles from 5 to 1 microneedle. Gardeniers et al.[51] have demonstrated that 
plasma concentration of diclofenac increases by increasing the number of microneedles. 
 
To obtain a theoretical perspective on the influence of the number of microneedles, the 
number was varied for model F. From Figure 1(b), the surface area for one needle is equal to 480 
the width multiply by the length ( 28 m101 −×  in the present case). Therefore, the total 
surface area of a given patch (Sa) has been defined to be the surface area for one needle 
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multiplies by the number of microneedles. This value has been used as an input parameter in 
SKIN-CAD® to describe patch surface area. We have also defined that the effective skin 
thickness for a patch to be the same as that for one micro-needle. All other dimensions have 485 
been kept constant as shown in Table 1. As expected, Figure 16 confirms that by increasing 
the number of microneedles, the maximum insulin concentration in blood (Cb,max) also 
increases. This is expected as Sa is a linear function of the number of microneedles and in turn 
the insulin concentration in blood Cb is a linear function of Sa. 
 490 
The number of microneedles in the array (N) of each microneedle models was varied to study 
the influence on blood insulin concentration of coated insulin as shown in Figure 17. As 
explained previously, microneedle model A and microneedle model C have been found to be 
indistinguishable so the results for microneedle model C have not been plotted. Microneedle 
model D results in the highest maximum insulin concentration in blood (Cb,max) with a value 495 
of 1.9 ng/ml corresponding to a microneedle number of 500. For the range of N studied, the 
maximum insulin concentration in the blood varied significantly, indicating that the maximum 
concentration is a very strong function of microneedle number. Indeed, microneedle number 
appears to be the most significant parameter of those examined.  The results indicate a 
proportional relationship between the number of microneedles in the array (N) and maximum 500 
insulin concentration in blood. 
 
4. Conclusion 
Insulin was chosen as a model drug to study the effects of microneedle geometry on blood 
concentration profiles.  A mathematical framework has been presented to this effect. The 505 
maximum insulin concentration in blood (Cb,max) was also calculated for various microneedle 
models. The influence of microneedle geometry has been discussed and compared for various 
microneedles models. However, as many parameters determine insulin transport from 
microneedle arrays, there is scope to further study these issues in future work.  
 510 
For the purpose of this paper a range of microneedle models have been utilised. The 
distribution of insulin across skin for all the microneedles models has been investigated. For 
the geometrical parameters chosen, it seems that the most effective microneedle model in 
terms of the distribution of insulin concentration is the rocket needle that has a constant tip 
angle of 90º (i.e., microneedle model D). Also, it has been found that the number of 515 
microneedles in an array is the most significant factor in determining maximum insulin 
concentration in blood (Cb,max). This was expected as the insulin concentration in blood has a 
proportional relationship with the surface area of the array which is in turn proportional to the 
number of microneedles in the array. Penetration depth of the microneedle, centre-to-centre 
spacing and microneedle thickness had a less significant effect on the maximum insulin 520 
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concentration in the blood. No differences have been observed in the maximum insulin 
concentration in the blood by varying the other microneedle parameters (i.e. coating depth of 
the microneedles, microneedle diameter). Moreover, it has been observed that the optimum 
microneedle model in terms of varying microneedle diameter was microneedle model A. 
Microneedle model D was the best model in terms of the other microneedle dimensions. 525 
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6. Nomenclature 
C concentration of insulin (unit/m3) 
Cb insulin concentration in the blood (ng/ml) 
Cb,max maximum insulin concentration in the blood (ng/ml) 535 
CD depth of insulin coating (µm) 
Cm concentration of insulin in the microneedle coating (unit/m3) 
Cm0 initial concentration of insulin in the microneedle (unit/m3) 
D diffusion coefficient (m2/s) 
d microneedle diameter (µm) 540 
Dvs diffusion coefficient of insulin in the viable skin 
h epidermis thickness (µm) 
H thickness of the skin after inserting the microneedle (µm) 
Heff effective thickness of the skin after inserting the microneedle (µm) 
ssJ  average steady state flux (unit/m
2s) 545 
Ke elimination rate constant from the blood compartment (1/h) 
L penetration depth of microneedles (µm) 
Lu length of the uncoated microneedles (µm) 
N number of microneedles in the array (-) 
P permeability of insulin in skin (m/s) 550 
Peff effective skin permeability of drug (m/s) 
S centre-to-centre spacing of microneedles (µm) 
Sa surface area of the microneedle patch (m2) 
t time (s) 
T microneedle thickness (µm) 555 
Vb volume of distribution in the blood (L) 
x path length of insulin molecules in a given skin layer (µm ) 
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dQ/dt penetration rate of insulin through the skin (µg/cm2 h) 
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Table 1. The standard design parameters of each microneedle model (Figure 1) 
 
*Penetration depths (L) of all microneedles models represent the depth to which the 
microneedles penetrate the skin, and as such, does not directly represent the physical length of 
the microneedle as shown in Figure 1. 
# The difference between the penetration depth (L) and the length of the uncoated 
microneedles (Lu) is the coating depth (L-Lu) 
Model   Penetration 
Depth* 
 (µm) 
Diameter 
(µm) 
Width 
(µm) 
Thickness 
(µm) 
Spacing 
(µm) 
Coating 
Depth#  
(µm) 
Number 
in array 
(-) 
A 140 50 - - 100 100 100 
B 140 50(at base) - - 100 100 100 
C 140 50 - - 100 100 100 
D 140 - 50 35 100 100 100 
E 140 - shaft tip 35 100 100 100 
30 60 
F 140 - 50 35 100 100 100 
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Figure 1. Schematic of coated microneedles for transdermal insulin delivery: (a) side view, 
(b) top view. H is the thickness of the skin after microneedles have been inserted (i.e., the 
distance between the tip of the microneedle and the blood microcirculation), h is the 
epidermis thickness, L is the penetration depth of microneedles, Lu is the length of the 
uncoated microneedles and S is the centre-to-centre spacing. 
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Figure 2. The six microneedle models used in this study adopted from Davidson et al.[24]. 
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Figure 3. Comparison of the simulated blood concentration profile of insulin after applying 
transdermal delivery by microneedle model F (black column) and the experimental results 
(blank column) assuming the insertion time of microneedles to be four hours. 
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Figure 4. Distribution of Insulin in skin for microneedle models (A), (B) and (C) (penetration 
depth is 140 µm and all the remaining dimensions with their standard values as mentioned in 
Table 1). 
Drug concentration (unit/m3) 
Microneedle Model (A) Microneedle Model (B) Microneedle Model (C) 
Sk
in
 d
ep
th
 (µ
m
) 
Spacing (µm) 
Spacing (µm) 
 
 
25
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Distribution of Insulin in skin for microneedle models (D), (E) and (F) (penetration 
depth is 140 µm and all the remaining dimensions with their standard values as mentioned in 
Table 1). 
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Figure 6. Influence of the penetration depth (L) of microneedle model (A) on insulin 
concentration in blood, assuming that the insertion time of microneedles is four hours. 
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Figure 7. Influence of the penetration depth (L) of various microneedles models, coated with 
insulin, on the maximum insulin concentration in blood (Cb,max), assuming that the insertion 
time of microneedles is four hours (the results of microneedle model C are not included in the 
figure as they are very similar to the results of microneedle model A). 
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Figure 8. Influence of the centre-to-centre spacing (S) of microneedle model (B) on insulin 
concentration in blood, assuming that the insertion time of microneedles is four hours. 
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Figure 9. Influence of the centre-to-centre spacing (S) of various microneedles models, coated 
with insulin, on the maximum insulin concentration in blood (Cb,max), assuming that the 
insertion time of microneedles is four hours (the results of microneedle model C are not 
included in the figure as they are very similar to the results of microneedle model A). 
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Figure 10. Influence of the diameter (d) of microneedle model (C) on insulin concentration in 
blood, assuming that the insertion time of microneedles is four hours. 
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Figure 11. Influence of the diameter (d) of various microneedles models, coated with insulin, 
on the maximum insulin concentration in blood (Cb,max), assuming that the insertion time of 
microneedles is four hours. 
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Figure 12. Influence of the coating depth (CD) of microneedle model (D) on insulin 
concentration in blood, assuming that the insertion time of microneedles is four hours. 
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Figure 13. Influence of the coating depth (CD) of various microneedles models, coated with 
insulin, on the maximum insulin concentration in blood (Cb,max), assuming that the insertion 
time of microneedles is four hours (the results of microneedle model C are not included in the 
figure as they are very similar to the results of microneedle model A). 
 
 
M
ax
im
um
 in
su
lin
 c
on
ce
nt
ra
tio
n 
in
   
  
   
   
   
 b
lo
od
, C
b,
m
ax
 (n
g/
m
l) 
 
Coating depth, CD (µm) 
0.22
0.24
0.26
0.28
0.3
0.32
0.34
0.36
0.38
0.4
40 50 60 70 80 90 100
Model A Mode B Model D Model E Model F
 
 
34
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Influence of the thickness (T) of microneedle model (E) on insulin concentration in 
blood, assuming that the insertion time of microneedles is four hours. 
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Figure 15. Influence of the microneedle thickness (T) of various microneedles models, coated 
with insulin, on the maximum insulin concentration in blood (Cb,max), assuming that the 
insertion time of microneedles is four hours (the dimensions of these microneedle models are 
as illustrated in Table 1). 
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Figure 16. Influence of the number of microneedles in the array (N) of microneedle model (F) 
on insulin concentration in blood, assuming that the insertion time of microneedles is four 
hours. 
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Figure 17. Influence of the total number of microneedles (N) of various microneedles models, 
coated with insulin, on the maximum insulin concentration in blood Cb,max, assuming that the 
insertion time of microneedles is four hours (the results of microneedle model C are not 
included in the figure as they are very similar to the results of microneedle model A). 
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